体内研究 (In Vivo) |
Anrikefon (HSK21542) (0.03-30 mg/kg; i.v.; single dose) 在 Mus musculus 醋酸扭体模型中可产生强效、剂量依赖性、由 KOR 介导的镇痛作用,给药后 15 分钟的最低有效剂量为 0.03 mg/kg,且药效至少可持续至给药后 24 小时。 Anrikefon (HSK21542) (0.1-10 mg/kg; i.v.; single dose) 在大鼠后爪切口术后疼痛模型中可产生剂量依赖性的抗异常痛觉效应,当给药剂量为 3 mg/kg 和 10 mg/kg 时,其药效在给药后至少 24 小时仍可检测到。 Anrikefon (HSK21542) (0.1-3 mg/kg; i.v.; single dose) 在大鼠 CCI 神经病理性疼痛模型中可产生具有剂量依赖性的持续抗异常痛觉作用,其最低有效剂量为 0.3 mg/kg,且在 1 mg/kg 和 3 mg/kg 剂量下,给药后药效至少持续 24 小时。 Anrikefon (HSK21542) (0.01-3 mg/kg; i.v.; single dose) 在化合物 48/80 诱导的小鼠搔抓模型中可产生强效的、剂量依赖性止痒作用,其最低有效剂量为 0.03 mg/kg,在 1 mg/kg 剂量下可实现近乎完全抑制。 Anrikefon (HSK21542) (3.75-7.5 mg/kg; i.v.; single dose) 在小鼠热板试验中表现出较弱的中枢镇痛作用,其最小有效剂量为 7.5 mg/kg,显著高于发挥外周镇痛和止痒活性所需的剂量。 Anrikefon (HSK21542) (0.4-2 mg/kg; i.v.; single dose) 仅在较高剂量 (2 mg/kg) 时对 Rattus norvegicus(rats) 产生轻度镇静作用,在最高达 0.4 mg/kg 的剂量下无显著作用。 Anrikefon (HSK21542) (0.4-2 mg/kg; i.v.; single dose) 在剂量高达 2 mg/kg 时不会显著改变小鼠的呼吸频率,表明其具有良好的呼吸安全性特征。 Anrikefon (1-10 mg/kg/天;静脉注射;每 6 小时给药 1 次,每日 2 次) 在剂量高达 10 mg/kg/天时对雄性大鼠的生育力或早期胚胎发育无具有毒理学意义的影响,但在所有受试剂量下会延长雌性大鼠的动情周期时长并提高紊乱率,导致雌性生育力毒性的 NOAEL 低于 1 mg/kg/天。 Anrikefon (0.2-4 mg/kg/天;静脉注射;每 6 小时给药 1 次,每日 2 次) 对 rats 的胚胎-胎仔发育的 NOAEL 为 1 mg/kg/天,仅在 4 mg/kg/天剂量下观察到胸椎椎体骨化不完全的发生率略有升高。 Anrikefon (0.3-2 μg/kg/日;静脉注射;每日给药) 对家兔胚胎-胎仔发育的 NOAEL 为 2 μg/kg/日,在所有受试剂量下均未观察到具有毒理学意义的不良反应。 Anrikefon (0.2-4 mg/kg/day; i.v.; twice a day at 6-hour intervals) 对大鼠的出生前后发育的 NOAEL 为 4 mg/kg/天,在所有测试剂量下均未观察到对母鼠或子代相关指标具有毒理学意义的不良反应。
| Animal Model: |
ICR (18-22 g, 8-10 weeks old, half male and half female; acetic acid-induced writhing modeling) |
| Dosage: |
0.03-30 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 27.46% inhibitory rate on writhing behaviors at 0.03 mg/kg (15 minutes post-dosing). Produced dose-dependent increases in inhibitory efficacy at 0.1 mg/kg and higher doses (15 minutes post-dosing), with effects comparable to CR845 at equivalent doses. Reached a median effective dose (ED50) of 0.09 mg/kg (95% CI: 0.06-0.12 mg/kg) at 15 minutes post-dosing. Induced a 32.75% inhibitory rate at 0.3 mg/kg (24 hours post-dosing). Induced a 49.67% inhibitory rate at 1 mg/kg (24 hours post-dosing). Induced a 55.60% inhibitory rate at 3 mg/kg (24 hours post-dosing). Induced a 68.12% inhibitory rate at 10 mg/kg (24 hours post-dosing). Induced a 75.16% inhibitory rate at 30 mg/kg (24 hours post-dosing). Reached an ED50 of 1.48 mg/kg (95% CI: 0.62-2.45 mg/kg) at 24 hours post-dosing. Showed antinociceptive effects at 0.3 mg/kg and 1 mg/kg that were completely reversed by pre-treatment with nor-binaltorphimine. |
| Animal Model: |
Sprague Dawley (SD) (160-180 g, 8-10 weeks old, male; hindpaw incision modeling) |
| Dosage: |
0.1-10 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 10.5-fold increase in 50% paw withdrawal threshold (PWT; 7.51 g vs. 0.72 g in vehicle controls) at 1 mg/kg (15 minutes post-dosing). Produced maximum antiallodynic activity at 10 mg/kg (15 minutes post-dosing). Had a minimum effective dose (MED) of 1 mg/kg. Maintained statistically significant increases in mechanical pain thresholds at 3 mg/kg and 10 mg/kg compared to vehicle controls (24 hours post-dosing). |
| Animal Model: |
Sprague Dawley (SD) (160-180 g, 8-10 weeks old, male; chronic constriction injury [CCI] modeling) |
| Dosage: |
0.1-3 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Induced a 5.15-fold increase in 50% PWT (6.62 g vs. 1.29 g in vehicle controls) at 0.3 mg/kg (15 minutes post-dosing). Produced peak 50% PWT values at 2 hours post-dosing at 1 mg/kg and 3 mg/kg, which gradually declined but remained significantly elevated compared to vehicle controls at 24 hours post-dosing. Showed a significantly increased AUC for 50% PWT over time at all doses tested, with the MED defined as 0.3 mg/kg. |
| Animal Model: |
ICR (18-22 g, 8-10 weeks old, male; compound 48/80-induced scratching modeling) |
| Dosage: |
0.01-3 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Produced dose-dependent inhibition of scratching behaviors. Induced a 34.89% inhibitory rate at 0.03 mg/kg. Induced a 53.02% inhibitory rate at 0.1 mg/kg. Induced a 73.75% inhibitory rate at 0.3 mg/kg. Induced a peak 99.78% inhibitory rate at 1 mg/kg. Had a MED of 0.03 mg/kg, and an ED50 of 0.09 mg/kg (95% CI: 0.04-0.16 mg/kg), with efficacy comparable to CR845 at equivalent doses. |
| Animal Model: |
C57BL/6J (18-22 g, 8-10 weeks old, female) |
| Dosage: |
3.75-7.5 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not produce a significant increase in % MPE at 3.75 mg/kg. Induced a 29.60% MPE at 7.5 mg/kg, which was statistically significant compared to vehicle controls. Reached an ED50 of 10.49 mg/kg (95% CI: 7.58-15.37 mg/kg). |
| Animal Model: |
Sprague Dawley (SD) (160-180 g, 8-10 weeks old, half male and half female) |
| Dosage: |
0.4 mg/kg; 2 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not produce a significant reduction in total distance traveled compared to vehicle controls at 0.4 mg/kg. Induced a statistically significant reduction in locomotor activity at 2 mg/kg. |
| Animal Model: |
ICR (18-22 g, 8-10 weeks old, half male and half female) |
| Dosage: |
0.4 mg/kg; 2 mg/kg |
| Administration: |
i.v.; single dose |
| Result: |
Did not produce a statistically significant change in respiratory rate compared to vehicle controls at 0.4 mg/kg or 2 mg/kg at any time point tested. |
| Animal Model: |
Sprague-Dawley rats (8-11 weeks, both sexes, fertility and early embryonic development model) |
| Dosage: |
1 mg/kg/day; 3 mg/kg/day; 10 mg/kg/day |
| Administration: |
i.v.; twice a day at 6-hour intervals; males: 4 weeks prior to mating through mating period until day before necropsy; females: 2 weeks prior to mating through mating period until gestation day 15 |
| Result: |
Increased male rat sperm count to 440.6 ×10^6 (1 mg/kg/day) and 436.7 ×10^6 (10 mg/kg/day).\nIncreased male rat sperm density to 704.1 ×10^6/g (1 mg/kg/day) and 722.4 ×10^6/g (10 mg/kg/day).\nLeft male rat sperm motility and malformation rate unchanged across all doses.\nIncreased female rat estrous cycle length to 4.4 days (1 mg/kg/day), 4.5 days (3 mg/kg/day), and 4.6 days (10 mg/kg/day).\nIncreased female rat estrous cycle disorder rate to 65.4% (1 mg/kg/day), 61.5% (3 mg/kg/day), and 57.7% (10 mg/kg/day).\nIncreased female rat precoital interval to 3.2 days (10 mg/kg/day).\nDecreased female rat gravid uterus weight to 15.805 g (1 mg/kg/day).\nLeft female rat copulation index, conception index, fertility index, corpora lutea count, implantation sites, resorptions, viable embryos, and pre/post-implantation loss unchanged across all doses. |
| Animal Model: |
Sprague-Dawley rats (pregnant females, embryo-fetal developmental model) |
| Dosage: |
0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day |
| Administration: |
i.v.; twice a day at 6-hour intervals; gestation day 6 through gestation day 17 |
| Result: |
Caused transient, mild decreases in maternal rat body weight (3.56-6.33%) from GD 8 to GD 10 in the 1 and 4 mg/kg/day groups.\nDecreased maternal rat food consumption from GD 6 to GD 7 across all doses.\nLeft maternal rat corpora lutea count, implantation sites, resorptions, viable fetuses, post-implantation loss, and organ weights unchanged across all doses.\nLeft fetal rat weight and crown-rump length unchanged across all doses.\nIncreased the incidence of fetuses with incomplete ossification of thoracic vertebral centrum by 3.5% in the 4 mg/kg/day group.\nDecreased incomplete ossification of pubis, hyoid bone, and 5th/6th sternebra in the 1 mg/kg/day group, and decreased incomplete ossification of hyoid bone in the 4 mg/kg/day group (deemed not toxicologically significant).\nIncreased 14th rudimentary ribs in the 4 mg/kg/day group (deemed incidental). |
| Animal Model: |
New Zealand white rabbits (5-6 months, pregnant females, embryo-fetal developmental model) |
| Dosage: |
0.3 μg/kg/day; 1 μg/kg/day; 2 μg/kg/day |
| Administration: |
i.v.; daily; gestation day 7 through gestation day 19 |
| Result: |
Left maternal rabbit body weight, food consumption, corpora lutea count, implantation sites, resorptions, viable fetuses, post-implantation loss, and organ weights unchanged across all doses.\nLeft fetal rabbit weight and crown-rump length unchanged across all doses.\nDecreased male fetus ratio to 32% in the 2 μg/kg/day group (deemed not toxicologically significant).\nLeft fetal rabbit external, visceral, and skeletal malformations or variations unchanged across all doses. |
| Animal Model: |
Sprague-Dawley rats (pregnant females and their offspring, pre- and post-natal development model) |
| Dosage: |
0.2 mg/kg/day; 1 mg/kg/day; 4 mg/kg/day |
| Administration: |
i.v.; twice a day at 6-hour intervals; gestation day 6 through postnatal day 21 |
| Result: |
Caused transient, mild decreases in maternal rat body weight (4.04-6.56%) from GD 8 to GD 17 in the 1 and 4 mg/kg/day groups (deemed not treatment-related).\nDecreased maternal rat food consumption from GD 6 to GD 7 in the 1 and 4 mg/kg/day groups, and increased food consumption from GD 10 to GD 11 in the 1 mg/kg/day group (deemed not treatment-related).\nIncreased maternal rat resorptions in the 1 mg/kg/day group (deemed not toxicologically significant).\nLeft maternal rat gestation length, corpora lutea count, implantation sites, viable fetuses, post-implantation loss, litter size, and live birth/viability/lactation indices unchanged across all doses.\nLeft offspring pre-weaning and post-weaning body weights largely unchanged, with minor, non-toxicologically significant increases in female offspring body weight on PND 63 and 70 at 1 and 4 mg/kg/day.\nLeft offspring reflex development, locomotor activity, learning behavior, sexual maturation, and reproductive capacity unchanged across all doses.\nIncreased offspring placenta weight in the 4 mg/kg/day group (deemed not toxicologically significant). |
|